Sponsors (23)
Requires Medicaid coverage and separate payment for whole genome and whole exome sequencing when ordered as a first‑tier test for suspected genetic or unexplained conditions in children.
The bill expands access to genomic sequencing for Medicaid children and increases transparency and planning around implementation, but it raises Medicaid costs, creates implementation burdens, and could still leave gaps if payment rates or clinical safeguards are not well calibrated.
Medicaid-enrolled children with suspected genetic disorders will gain coverage for whole-genome or whole-exome sequencing as a covered medical service, expanding access to diagnostic testing and likely speeding diagnosis and appropriate care.
States must pay separately for sequencing instead of bundling it into broader payments, improving reimbursement transparency and encouraging laboratories and providers to offer testing to Medicaid patients.
HHS-led outreach, stakeholder convenings, and a GAO assessment will identify implementation barriers (e.g., prior authorization, workforce) and produce recommendations to improve access within about two years.
Expanding Medicaid-covered sequencing will increase Medicaid spending, potentially pressuring state budgets or requiring changes in federal/state funding or priorities.
If provider payment rates are set too low or misaligned with market costs, labs and genetic counselors may receive inadequate reimbursement, limiting provider participation despite the coverage mandate.
Requiring sequencing as a 'first-tier' test in specified cases could increase utilization and risk overuse in borderline cases if clinical criteria and prior-authorization safeguards are not well-defined.
Based on analysis of 2 sections of legislative text.
Official title: To amend title XIX of the Social Security Act to clarify that whole genome and whole exome sequencing for children with certain medical needs is covered under the Medicaid program.
Introduced January 15, 2026 by Scott Peters · Last progress January 15, 2026
Requires Medicaid to cover whole genome sequencing (WGS) and whole exome sequencing (WES) for children when ordered as a first‑tier diagnostic test for suspected genetic disorders, rare diseases, or unexplained conditions (including congenital anomalies, global developmental delay, or intellectual disability). It defines sequencing and associated analysis, directs separate payment (not bundled), mandates HHS outreach and a report on state payment and utilization, instructs GAO to evaluate program impacts and make recommendations, and sets an effective date of January 1, 2027.